February 7, 2014
The landscape of hepatitis C (HCV) management has undergone a near-fundamental transformation over the past couple of years. As new treatment options puff up like popcorn kernels on a hot stove and our understanding of the virus deepens, it's important to revisit what's changed -- and what further changes 2014 may hold in store.
Late in 2013, Andrea Cox, M.D., Ph.D., an associate professor of medicine at Johns Hopkins University School of Medicine, presented an update on HCV coinfection for an audience of HIV care providers. Read on for a summary of key points from her talk, including selected slides (which have been reposted with her permission).
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|Which Hepatitis C Treatment to Start in 2016|
|This Week in HIV Research: Antibody Suppresses HIV; Investigational Drug BMS-986001; and Quality of Care on Mortality|
|This Week in HIV Research: Smoking Associated With Poor HIV Outcomes; How Gay Men Decide on Condomless Sex; and More|
|High Liver Enzymes Signal Serious Disease in HIV-Positive Individuals Without Hepatitis|
|This Week in HIV Research: Tenofovir Resistance Alarmingly Common; Ongoing HIV Replication Replenishes Reservoirs; and More|
|Dolutegravir: A Powerful Drug Entering Different Research Paths|